National Cancer Institute grant awarded:

RiboMed has been awarded a Phase I SBIR grant from the National Cancer Institute under its Innovative Molecular Analysis Technologies Program (IMAT). The grant, entitled “Abscription™-Based CpG Methylation Assays for Early Cancer Detection” involves development of a bisulfate-free method for detecting gene methylation associated with tumor suppressor genes.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s